A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DRUG: Lorlatinib
Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per Independent Central Radiology (ICR) assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
Duration of response (DoR) as assessed by RECIST v1.1 per ICR assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|ORR assessed by RECIST version 1.1 per investigator assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|DoR assessed by RECIST version 1.1 per investigator assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Disease control rate (DCR) at 12 and 24 week as assessed by RECIST v1.1 per ICR assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Time to tumor response (TTR) as assessed by RECIST v1.1 per ICR assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Progression-free survival (PFS) as assessed by RECIST v1.1 per ICR assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Intracranial Objective Response (IC-OR) as assessed by RECIST v1.1 per ICR assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Duration of intracranial response (IC-DoR) as assessed by RECIST v1.1 per ICR assessment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Overall survival (OS), From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|To evaluate the safety and tolerability of lorlatinib treatment, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|Lorlatinib concentration will be used for population PK analysis, From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months|patient-reported outcomes (PROs) as assessed by EORTC QLQ-C30 and EORTC QLQ-LC13 (self-assessment questionnaires), From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China